12:00 AM
 | 
Mar 26, 2007
 |  BioCentury  |  Product Development

Reaching proof of concept

Reaching proof of concept

Obesity
Company Product Description Target/ Mechanism Milestones
Alizyme Cetilistat (ATL-962) Lipase inhibitor Lipase Start Ph III 1H07 (A)
Amylin Pramlintide/leptin Synthetic amylin analog/recombinant leptin Amylin receptor/leptin receptor Ph II data 07 (A)
GlaxoSmithKline/ Kissei Sergliflozin (869682, KGT-1251) Sodium-glucose cotransporter 2 (SGLT2) inhibitor SGLT2 NA
Innodia Adyvia (ID...

Read the full 367 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >